VIDAS® LYME IgM II
VIDAS® LYME IgG II
Is your laboratory prepared for Lyme disease?


The VIDAS Lyme IgG II assay contains a combination of 3 recombinant chimeric *Borrelia burgdorferi* sensu lato proteins (VlsE, DbpA, and OspC).

- Outer surface proteins (OspC, DbpA, VlsE) play a major role in the immune response of the infected host. Additionally, all three antigens used in these assays have been shown to be immunogenic during human infection.5

- OspC (Outer surface protein C) is essential to establish *Borrelia* infection, essentially produced in vivo.

- DbpA (Decorin-binding protein A) outer surface protein produced by *Borrelia*, essentially in vivo.

- VlsE (Variable major protein-like sequence), expressed in vivo presents a highly immunogenic conserved region, used for serodiagnosis.

“When using the LYM/LYG EIAs as a first-tier test followed by the C6 EIA as a second tier-test, it should be noted that the LYG EIA uses VlsE as one of three test antigens. VlsE is an immunogenic variable surface protein of *B. burgdorferi* that contains two invariable domains at each terminus, and a central domain that is composed of six variable and six invariable regions (IRs).2,3 C6 is the sixth invariable region (IR6) of the central domain of VlsE.”4

Less rework and clinically unnecessary confirmatory tests.5
ADVANTAGES

Differentiated serological profile
- Facilitates classification of Lyme borreliosis: early or late/chronic, active or immune
- Helps ensure patients receive rapid, optimized treatment depending on their stage of infection
- Potential to deduce information on disease progression (based on IgG and/or IgM positivity)\(^5\)

Better patient management\(^1\) and only patients with Lyme borreliosis are treated
- Innovative recombinant chimeric proteins (VlsE, DbpA, OspC) allowing detection of all main pathogenic *Borrelia* strains (sensu stricto, *afzelii, garinii*). The design of the chimeric protein constructs includes C6 (the VlsE invariant region IR6), which allows the VIDAS Lyme IgG II assay to provide high sensitivity and specificity and limit cross-reactivity
- Low level of cross-reaction (syphilis, other infectious diseases)

Easy result interpretation
- No equivocal zone for VIDAS Lyme IgG II results
- Avoid unnecessary patient anxiety and additional testing

Streamlined workflow, rapid results
- Results in 27 minutes
- Calibration only once every 28 days
- Ease-of-use
- Single-dose tests

Cost effective\(^5,6\)
- Decreased number of total immunoblots that are needed for second-tier testing
- Reduction in costs associated with immunoblots
- Reduction in the level of specialized training that is required to properly perform an EIA as compared to immunoblotting
REFERENCES

1. VIDAS® LYME IgG II and VIDAS® LYME IgM II package inserts